![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
In the face of the cruel financial turmoil, venture capitalists are shrinking their front lines. The severe cold on Wall Street has directly threatened the capital chain and innovative R&D efficiency of small and medium-sized biotech companies. Small and medium-sized biotech companies are eager to see large pharmaceutical companies that have sufficient cash flow to come to the rescue.
Pfizer has also repeatedly emphasized that it will increase its risk investment efforts, and other large pharmaceutical companies in the industry such as Johnson & Johnson and GlaxoSmithKline, etc., make full use of the company's internal venture capital institutions and actively seek investment opportunities.
The most talked about by Pfizer executives at the recent AusBiotech2008 meeting in Australia, which is just concluded, is how to take advantage of the capital and clinical advantages of large pharmaceutical companies and provide SMEs with venture capital for drug innovation research and development.
Pfizer’s intentions in this area are becoming more and more obvious, and it has a certain representation in the pharmaceutical industry. Barbara Dalton, Pfizer's vice president of venture capital investment management, made it clear at the meeting that the company is actively looking for strategic partners to enrich its new drug product library in the hope of obtaining future investment returns.
The AusBiotech conference is the largest industry conference in the Australian biopharmaceutical industry and brings together more than 1,400 attendees from Asia Pacific. At the conference, industry giant CSL announced that it will acquire and fully control its previous collaborative research program with MuriGen Therapeutics to develop innovative drugs for the treatment of arthritis and inflammatory diseases.
In the past 11 months, the IPOs of biotechnology companies have been at a standstill, and venture capital institutions are also reluctant to continue to invest in additional investments. Biotechnology companies focused on innovative R&D are facing huge financial pressure and survival risks. The big pharmaceutical companies are willing to take the initiative in this very period. It is a disaster for the small and medium-sized biotech companies that lack funds. At the same time, for large pharmaceutical companies with sufficient cash but poor new products and weak stocks, the injection of small companies can also solve their immediate needs and provide impetus for future growth.
The turmoil in the capital market has kept the life sciences company from stagnating. From the perspective of adjusting the “ecology†of the capital market and the balance between supply and demand, pharmaceutical giants like Pfizer are using their own funds to play the part of previous venture investors. To provide companies with potential for development with the necessary financial support. Dalton said, "Many pharmaceutical companies now like to use venture capital as a tool to establish good relationships with biotech companies around the world."
In the past year, Pfizer cut R&D and sales personnel, established biotechnology research and development and investment companies, strengthened cooperation with outsourcing units, increased support for the company's venture capital department and foreign investment, and established close contact with California. A large biomedical incubator for academic research institutions. This series of measures is not surprising for large pharmaceutical companies keen on investing in drug development. It is imperative for big pharmaceutical companies to fill and enrich their R&D lines.
After Pfizer has suffered several major project failures, it may face greater pressure. Therefore, Pfizer has repeatedly stated that it is necessary to expand the horizons of finding strategic partners and explore new modes of innovation and cooperation. The goal and taste of Pfizer's search for new drugs is not limited to the biopharmaceutical companies that Pfizer invests in and shares in the United States. As long as it meets Pfizer's product development strategy, any new drug product and company with innovative potential will have the opportunity to cooperate with Pfizer.
“Our investment field must consider whether there is commercial complementary value and strategic partnership with Pfizer, and we must also look at the financial returns of its investment.†Dalton had several Australian biotechs during the conference. The company management meeting, she bluntly told these potential partners and investment targets, Pfizer intends to trade 6-8 investment transactions in Australia each year, "there are good scientific foundations in Australia will certainly have some excellent investment opportunities." .
“Regardless of where, as long as it has good scientific creativity and the desire to transform scientific research results, coupled with good applied research and mechanisms, there will be good business opportunities and it may eventually be successfully accepted by the market.â€
However, traditionally speaking, small and medium-sized R&D companies that are in an early stage of development will have a hard time gaining favor from large pharmaceutical companies.
Pfizer has also repeatedly emphasized that it will increase its risk investment efforts, and other large pharmaceutical companies in the industry such as Johnson & Johnson and GlaxoSmithKline, etc., make full use of the company's internal venture capital institutions and actively seek investment opportunities.
The most talked about by Pfizer executives at the recent AusBiotech2008 meeting in Australia, which is just concluded, is how to take advantage of the capital and clinical advantages of large pharmaceutical companies and provide SMEs with venture capital for drug innovation research and development.
Pfizer’s intentions in this area are becoming more and more obvious, and it has a certain representation in the pharmaceutical industry. Barbara Dalton, Pfizer's vice president of venture capital investment management, made it clear at the meeting that the company is actively looking for strategic partners to enrich its new drug product library in the hope of obtaining future investment returns.
The AusBiotech conference is the largest industry conference in the Australian biopharmaceutical industry and brings together more than 1,400 attendees from Asia Pacific. At the conference, industry giant CSL announced that it will acquire and fully control its previous collaborative research program with MuriGen Therapeutics to develop innovative drugs for the treatment of arthritis and inflammatory diseases.
In the past 11 months, the IPOs of biotechnology companies have been at a standstill, and venture capital institutions are also reluctant to continue to invest in additional investments. Biotechnology companies focused on innovative R&D are facing huge financial pressure and survival risks. The big pharmaceutical companies are willing to take the initiative in this very period. It is a disaster for the small and medium-sized biotech companies that lack funds. At the same time, for large pharmaceutical companies with sufficient cash but poor new products and weak stocks, the injection of small companies can also solve their immediate needs and provide impetus for future growth.
The turmoil in the capital market has kept the life sciences company from stagnating. From the perspective of adjusting the “ecology†of the capital market and the balance between supply and demand, pharmaceutical giants like Pfizer are using their own funds to play the part of previous venture investors. To provide companies with potential for development with the necessary financial support. Dalton said, "Many pharmaceutical companies now like to use venture capital as a tool to establish good relationships with biotech companies around the world."
In the past year, Pfizer cut R&D and sales personnel, established biotechnology research and development and investment companies, strengthened cooperation with outsourcing units, increased support for the company's venture capital department and foreign investment, and established close contact with California. A large biomedical incubator for academic research institutions. This series of measures is not surprising for large pharmaceutical companies keen on investing in drug development. It is imperative for big pharmaceutical companies to fill and enrich their R&D lines.
After Pfizer has suffered several major project failures, it may face greater pressure. Therefore, Pfizer has repeatedly stated that it is necessary to expand the horizons of finding strategic partners and explore new modes of innovation and cooperation. The goal and taste of Pfizer's search for new drugs is not limited to the biopharmaceutical companies that Pfizer invests in and shares in the United States. As long as it meets Pfizer's product development strategy, any new drug product and company with innovative potential will have the opportunity to cooperate with Pfizer.
“Our investment field must consider whether there is commercial complementary value and strategic partnership with Pfizer, and we must also look at the financial returns of its investment.†Dalton had several Australian biotechs during the conference. The company management meeting, she bluntly told these potential partners and investment targets, Pfizer intends to trade 6-8 investment transactions in Australia each year, "there are good scientific foundations in Australia will certainly have some excellent investment opportunities." .
“Regardless of where, as long as it has good scientific creativity and the desire to transform scientific research results, coupled with good applied research and mechanisms, there will be good business opportunities and it may eventually be successfully accepted by the market.â€
However, traditionally speaking, small and medium-sized R&D companies that are in an early stage of development will have a hard time gaining favor from large pharmaceutical companies.
Runde produce end feed Brass Fittings for European market.the quality satisfy Kitemark,end feed brass fittings,EF brass fittings,solder joint brass fittings,EN1254 brass fittings,brass pressure fittings,wrot joint brass fittings.
end feed brass fittings,EF brass fittings,solder joint brass fittings,EN1254 brass fittings,brass pressure fittings,wrot joint brass fittings
Taizhou Runde Company , https://www.zjcopperfittings.com